Meloxicam sodium salt hydrate

C₁₄H₁₂N₃NaO₄S₂ · xH₂O

373.38 (anhydrous basis)

MFCD11046047

24278802

NA.77

Meloxicam sodium salt hydrate has been used:

• as a cyclooxygenase-2 (COX-2) inhibitor in solid Ehrlich tumor
• as an alternative to diclofenac nonsteroidal anti-inflammatory drugs (NSAID) to treat vultures
• as a reference standard in liquid chromatography electrospray ionisation mass spectrometry (LC-ESI/MS)
• to test its effect on prostaglandin (PGE2) production in lipopolysaccharide (LPS)-induced COX-2 protein expression in RAW246.7 cells

Meloxicam, a member of the oxicam family, is a non-steroidal anti-inflammatory drug (NSAID). It is synthesized from piroxicam with aryl and the pyridyl ring substitution. Meloxicam is a cyclooxygenase-2 (COX-2) inhibitor, it may be useful in treating inflammation and pain. Meloxicam has been shown to stop thymulin-induced increas in concentration of cytokines and Nerve growth factor (NGF) in the liver of rats. Meloxicam also suppresses tumor growth and may be capable of antagonizing cachexia in vitro. It promotes apoptosis in hepatocellular carcinoma.

This compound was developed by Boehringer Ingelheim. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

≥98% (HPLC)

powder

light yellow to dark yellow

DMSO: 5 mg/mL, clear

Boehringer Ingelheim

room temp

O.[Na+].CN1C(C(=O)Nc2ncc(C)s2)=C([O-])c3ccccc3S1(=O)=O

1S/C14H13N3O4S2.Na.H2O/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2;;/h3-7,18H,1-2H3,(H,15,16,19);;1H2/q;+1;/p-1

IZBZAOZGNNQKPJ-UHFFFAOYSA-M

human ... PTGS2(5743)

100 mg in glass bottle

GHS06

Danger

H301 - H315 - H319 - H335

P301 + P310 + P330 - P302 + P352 - P305 + P351 + P338

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Respiratory system

6.1D - Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

WGK 3